Entrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Natarajan Sethuraman Sells 600 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 600 shares of the stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $18.00, for a total value of $10,800.00. Following the completion of the sale, the insider now directly owns 183,216 shares in the company, valued at $3,297,888. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Natarajan Sethuraman also recently made the following trade(s):

• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.09, for a total transaction of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.24, for a total transaction of $9,144.00.

Entrada Therapeutics Stock Down 1.1 %

Shares of Entrada Therapeutics stock opened at $17.44 on Friday. Entrada Therapeutics, Inc. has a 52 week low of $10.75 and a 52 week high of $18.17. The firm’s 50 day moving average is $16.01 and its two-hundred day moving average is $15.19. The firm has a market capitalization of $648.77 million, a P/E ratio of 5.89 and a beta of -0.25.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a net margin of 43.63% and a return on equity of 35.16%. The firm had revenue of $94.69 million for the quarter, compared to the consensus estimate of $55.00 million. As a group, research analysts expect that Entrada Therapeutics, Inc. will post 0.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TRDA has been the subject of several recent analyst reports. Oppenheimer reaffirmed an “outperform” rating and set a $25.00 price objective on shares of Entrada Therapeutics in a research report on Monday, August 26th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Entrada Therapeutics in a report on Wednesday, August 14th.

Institutional Trading of Entrada Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new position in Entrada Therapeutics during the 1st quarter worth approximately $79,000. SG Americas Securities LLC acquired a new stake in shares of Entrada Therapeutics in the third quarter valued at approximately $156,000. Allspring Global Investments Holdings LLC grew its position in shares of Entrada Therapeutics by 427.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after acquiring an additional 11,965 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Entrada Therapeutics by 25.3% in the 2nd quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after acquiring an additional 7,452 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in Entrada Therapeutics in the 2nd quarter valued at $636,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.